Dimerix News

News

Ticker

DXB.AX

ISIN

AU000000DXB7

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE News Documents

Dimerix Eulerpool News

Dimerix Stock News

Dimerix is being monitored by journalists and investors worldwide. We gather the latest Dimerix news here.

December 12 ·
Yahoo
ASX Penny Stocks To Consider In December 2025
September 5 ·
Yahoo
BKI Investment And 2 Other ASX Penny Stocks To Consider
June 22 ·
Yahoo
ASX Penny Stocks To Consider In June 2025
September 1 ·
Yahoo
Dimerix Full Year 2024 Earnings: AU$0.038 loss per share (vs AU$0.042 loss in FY 2023)

Dimerix Stock Press Releases

Dimerix regularly publishes news on the company's website that are relevant for investors.

Dimerix News 2026

This page contains all current news, analysis and press releases for Dimerix stock (DXB.AX, ISIN: AU000000DXB7). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at Dimerix.

Dimerix Stock

Dimerix Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future.